Analysts Set Insmed Incorporated (NASDAQ:INSM) Target Price at $94.00

Insmed Incorporated (NASDAQ:INSM - Get Free Report) has received an average recommendation of "Buy" from the sixteen research firms that are currently covering the stock, MarketBeat Ratings reports. Sixteen research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $94.00.

Several equities research analysts have issued reports on INSM shares. UBS Group lifted their target price on shares of Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Stifel Nicolaus reduced their target price on Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a research note on Friday, February 21st. Morgan Stanley lifted their price target on Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. Bank of America raised their price objective on Insmed from $92.00 to $96.00 and gave the company a "buy" rating in a report on Thursday, March 20th. Finally, Wells Fargo & Company increased their price target on shares of Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a research report on Wednesday, February 19th.

Insider Transactions at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $80.00, for a total value of $7,291,200.00. Following the completion of the sale, the insider now directly owns 97,083 shares in the company, valued at $7,766,640. This trade represents a 48.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO William Lewis sold 6,830 shares of the stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $70.16, for a total value of $479,192.80. Following the completion of the transaction, the chief executive officer now directly owns 233,924 shares of the company's stock, valued at $16,412,107.84. This represents a 2.84 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 471,797 shares of company stock worth $37,621,239. 3.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Insmed

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Elequin Capital LP bought a new position in shares of Insmed in the 4th quarter worth about $28,000. Steward Partners Investment Advisory LLC lifted its holdings in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 163 shares during the last quarter. NBC Securities Inc. bought a new stake in shares of Insmed in the 1st quarter worth approximately $49,000. V Square Quantitative Management LLC increased its position in Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 248 shares in the last quarter. Finally, Spire Wealth Management purchased a new position in Insmed during the fourth quarter valued at $47,000.

Insmed Price Performance

NASDAQ INSM traded down $3.14 on Thursday, hitting $69.51. The stock had a trading volume of 2,026,532 shares, compared to its average volume of 2,259,208. The firm has a 50-day moving average of $75.14 and a 200-day moving average of $73.59. The company has a market capitalization of $12.64 billion, a price-to-earnings ratio of -12.43 and a beta of 1.07. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed has a 52-week low of $21.92 and a 52-week high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $104.44 million for the quarter, compared to analysts' expectations of $102.31 million. Equities analysts expect that Insmed will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.